5月5日 - ** 药物开发商PTC Therapeutics PTCT.O股价盘前下跌20%至40美元
** 该公司称其治疗亨廷顿氏病的实验性药物达到了一项中期研究的主要目标
** 亨廷顿症是一种罕见的神经系统疾病,会损害人的思维、感觉和行动能力
** 这种名为 PTC518 的药物有助于显著降低血液中导致这种疾病的变异蛋白质的水平 - PTCT
** 加拿大皇家银行资本公司分析师说:"股价在数据公布后出现反弹,因此有些人可能一直在寻找无可争议的结果,但总体而言,我们认为初步数据看起来保持了该计划的前景,随着时间的推移,我们认为这应该是一个胜利。
** 截至上次收盘,股价年累计上涨约 11
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.